Go Pro
→ Trump Takes Emergency Action - Plus Elon Musk's New Venture (From Altimetry) (Ad)tc pixel Free MBRX Stock Alerts

Moleculin Biotech (MBRX) Financials

Moleculin Biotech logo
$2.12 +0.04 (+1.92%)
Closing price 07/24/2026 04:00 PM Eastern
Extended Trading
$2.12 0.00 (-0.24%)
As of 07/24/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Moleculin Biotech

Annual Income Statements for Moleculin Biotech

This table shows Moleculin Biotech's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -3.93 -9.81 -12 -13 -17 -16 -29 -30 -26 -34
Consolidated Net Income / (Loss)		 -3.93 -9.81 -12 -13 -17 -16 -29 -30 -26 -34
Net Income / (Loss) Continuing Operations		 -3.93 -9.81 -12 -13 -17 -16 -29 -30 -26 -34
Total Pre-Tax Income 		-3.93 -9.81 -12 -13 -17 -16 -29 -30 -26 -34
Total Operating Income		 -3.88 -8.65 -15 -18 -20 -23 -31 -30 -27 -25
Total Gross Profit		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Revenue		 0.00 0.00 0.00 0.00 0.00 - - 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 3.88 8.65 15 18 20 23 31 30 27 25
Selling, General & Admin Expense		 2.38 4.09 5.23 6.31 6.79 8.39 12 10 8.79 9.12
Research & Development Expense		 1.50 4.55 9.73 11 13 14 19 19 18 16
Depreciation Expense		 0.01 0.02 0.07 0.20 0.20 0.16 0.13 0.13 0.13 0.09
Total Other Income / (Expense), net		 -0.04 -1.15 3.15 4.09 2.36 7.03 1.62 -0.19 0.55 -8.44
Interest & Investment Income		 0.00 1.24 - - - - 0.24 1.37 0.55 0.11
Other Income / (Expense), net		 0.00 -2.39 3.15 4.08 2.35 6.73 1.38 -1.55 0.00 -8.54
Other Gains / (Losses), net		 - - - - 0.03 - - 0.05 0.04 -0.02
Preferred Stock Dividends Declared		 - - - - - - - - 0.00 0.10
Basic Earnings per Share		 ($0.40) ($0.53) ($0.46) ($1.95) ($1.76) ($0.59) ($15.22) ($15.07) ($189.14) ($28.42)
Weighted Average Basic Shares Outstanding		 9.83M 18.57M 25.90M 6.79M 9.85M 26.88M 1.91M 1.98M 137.72K 1.18M
Weighted Average Diluted Shares Outstanding		 9.83M 18.57M 25.90M 6.79M 9.85M 26.88M 28.63M 2.23M 14.00M 5.34M
Weighted Average Basic & Diluted Shares Outstanding		 9.83M 18.57M 25.90M 6.79M 9.85M 26.88M 28.63M 2.23M 14.00M 5.34M

Quarterly Income Statements for Moleculin Biotech

This table shows Moleculin Biotech's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -5.61 -10 -4.97 -4.32 -7.02 -9.74 -5.90 -7.64 -25 5.81 -15
Consolidated Net Income / (Loss)		 -5.61 -10 -4.97 -4.32 -7.02 -9.74 -5.90 -7.64 -25 5.92 -13
Net Income / (Loss) Continuing Operations		 -5.61 -10 -4.97 -4.32 -7.02 -9.74 -5.90 -7.64 -25 5.92 -13
Total Pre-Tax Income 		-5.62 -10 -4.98 -4.33 -7.03 -9.75 -5.91 -7.64 -25 5.96 -13
Total Operating Income		 -5.95 -8.92 -6.68 -6.19 -7.14 -6.64 -5.94 -5.72 -5.91 -7.53 -7.87
Total Gross Profit		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Operating Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 5.95 8.92 6.68 6.19 7.14 6.64 5.94 5.72 5.91 7.53 7.87
Selling, General & Admin Expense		 2.64 2.25 2.39 2.06 2.17 2.16 2.48 2.09 2.15 2.41 2.49
Research & Development Expense		 3.28 6.63 4.25 4.09 4.93 4.46 3.44 3.60 3.74 5.12 5.38
Depreciation Expense		 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.02 0.01 0.01
Total Other Income / (Expense), net		 0.33 -1.37 1.70 1.86 0.10 -3.10 0.03 -1.92 -20 13 -5.05
Interest & Investment Income		 0.32 0.26 0.24 0.16 0.10 0.05 0.03 0.03 0.04 0.01 0.03
Other Income / (Expense), net		 0.00 -1.63 1.46 1.70 0.00 -3.15 0.00 -1.95 -20 13 -5.08
Other Gains / (Losses), net		 0.01 0.02 0.01 0.01 0.01 0.01 0.01 0.00 0.02 -0.05 0.08
Preferred Stock Dividends Declared		 - - - - - - 0.00 - - - 1.77
Basic Earnings per Share		 ($2.82) ($5.20) ($2.02) ($1.70) ($1.89) ($70.69) ($15.80) ($0.49) ($0.68) $4.91 ($3.54)
Weighted Average Basic Shares Outstanding		 1.99M 1.98M 2.47M 2.54M 3.71M 137.72K 373.75K 15.53M 37.30M 1.18M 4.12M
Weighted Average Diluted Shares Outstanding		 29.81M 2.23M 2.31M 2.56M 3.00M 14.00M 14.13M 30.29M 50.91M 5.34M 5.34M
Weighted Average Basic & Diluted Shares Outstanding		 29.81M 2.23M 2.31M 2.56M 3.00M 14.00M 14.13M 30.29M 50.91M 5.34M 5.34M

Annual Cash Flow Statements for Moleculin Biotech

This table details how cash moves in and out of Moleculin Biotech's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 4.98 2.71 -0.58 3.60 4.44 56 -28 -20 -19 4.60
Net Cash From Operating Activities		 -3.77 -7.32 -12 -17 -18 -19 -28 -24 -24 -23
Net Cash From Continuing Operating Activities		 -3.77 -7.32 -12 -17 -18 -19 -28 -24 -24 -23
Net Income / (Loss) Continuing Operations		 -3.93 -9.81 -12 -13 -17 -16 -29 -30 -26 -34
Consolidated Net Income / (Loss)		 -3.93 -9.81 -12 -13 -17 -16 -29 -30 -26 -34
Depreciation Expense		 0.01 0.02 0.07 0.20 0.20 0.16 0.13 0.13 0.13 0.09
Non-Cash Adjustments To Reconcile Net Income		 0.41 1.92 -2.01 -2.05 -0.58 -4.26 1.03 4.43 1.83 10
Changes in Operating Assets and Liabilities, net		 -0.26 0.54 1.61 -2.14 -0.04 1.04 0.22 1.62 0.23 0.56
Net Cash From Investing Activities		 -0.12 -0.03 -0.42 -0.05 -0.37 -0.02 -0.07 -0.12 -0.01 0.00
Net Cash From Continuing Investing Activities		 -0.12 -0.03 -0.42 -0.05 -0.37 -0.02 -0.07 -0.12 -0.01 0.00
Purchase of Property, Plant & Equipment		 -0.02 -0.03 -0.42 -0.05 -0.38 -0.02 -0.07 -0.12 -0.01 0.00
Net Cash From Financing Activities		 8.87 10 12 21 23 75 -0.02 4.14 4.64 27
Net Cash From Continuing Financing Activities		 8.87 10 12 21 23 75 -0.02 4.14 4.64 27
Issuance of Common Equity		 9.17 6.07 12 19 23 75 0.00 4.17 4.66 26
Other Financing Activities, net		 0.00 3.99 0.02 1.56 -0.01 0.04 -0.02 -0.03 -0.03 1.52
Effect of Exchange Rate Changes		 - 0.00 - - 0.03 -0.02 -0.03 -0.02 -0.03 0.05

Quarterly Cash Flow Statements for Moleculin Biotech

This table details how cash moves in and out of Moleculin Biotech's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 -7.59 -1.03 -6.73 -5.98 -1.44 -5.13 3.44 -0.16 -0.85 2.18 1.44
Net Cash From Operating Activities		 -7.55 -4.90 -6.72 -5.95 -6.11 -5.08 -4.56 -5.58 -7.22 -5.37 -6.11
Net Cash From Continuing Operating Activities		 -7.55 -4.90 -6.72 -5.95 -6.11 -5.08 -4.56 -5.58 -7.22 -5.37 -6.11
Net Income / (Loss) Continuing Operations		 -5.61 -10 -4.97 -4.32 -10 -6.58 -5.90 -7.64 -35 16 -13
Consolidated Net Income / (Loss)		 -5.61 -10 -4.97 -4.32 -10 -6.58 -5.90 -7.64 -35 16 -13
Depreciation Expense		 0.03 0.04 0.03 0.03 0.03 0.03 0.03 0.03 0.02 0.01 0.01
Non-Cash Adjustments To Reconcile Net Income		 0.49 2.12 -0.85 -1.24 3.50 0.42 0.60 2.37 29 -23 5.60
Changes in Operating Assets and Liabilities, net		 -2.47 3.21 -0.93 -0.42 0.53 1.05 0.71 -0.34 -1.70 1.88 1.13
Net Cash From Investing Activities		 -0.03 -0.08 0.00 -0.01 - - 0.00 - - - 0.00
Net Cash From Continuing Investing Activities		 -0.03 -0.08 0.00 -0.01 - - 0.00 - - - 0.00
Net Cash From Financing Activities		 -0.00 3.96 0.00 -0.03 4.66 0.00 8.00 5.42 6.38 7.49 7.61
Net Cash From Continuing Financing Activities		 -0.00 3.96 0.00 -0.03 4.66 0.00 8.00 5.42 6.38 7.49 7.61
Issuance of Common Equity		 - 3.96 0.00 - 4.66 - 8.00 5.42 5.26 7.09 7.61
Other Financing Activities, net		 -0.00 - 0.00 -0.03 -0.00 0.00 0.00 0.01 1.11 0.40 0.00
Effect of Exchange Rate Changes		 -0.01 -0.01 -0.01 0.01 0.01 -0.05 0.00 - -0.01 0.05 -0.06

Annual Balance Sheets for Moleculin Biotech

This table presents Moleculin Biotech's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 0.03 16 19 20 25 29 84 57 38 17 22
Total Current Assets		 0.03 5.22 8.30 7.97 13 17 72 46 26 5.19 9.69
Cash & Equivalents		 0.03 5.01 7.71 7.13 11 15 71 43 24 4.28 8.88
Prepaid Expenses		 0.00 0.22 0.59 0.84 2.75 2.03 1.59 2.45 2.72 0.92 0.81
Plant, Property, & Equipment, net		 0.00 0.02 0.03 0.46 0.32 0.48 0.34 0.28 0.27 0.16 0.08
Total Noncurrent Assets		 0.00 11 11 11 11 11 11 12 12 12 12
Goodwill		 0.00 11 11 11 11 11 11 11 11 11 11
Other Noncurrent Operating Assets		 - - - - 0.29 0.20 0.11 0.40 0.52 0.42 1.21
Total Liabilities & Shareholders' Equity		 0.03 16 19 20 25 29 84 57 38 17 22
Total Liabilities		 0.77 1.43 2.37 5.31 9.66 11 5.10 5.23 12 5.72 7.12
Total Current Liabilities		 0.77 1.35 2.22 3.88 3.57 2.92 3.62 4.82 6.82 5.36 6.85
Accounts Payable		 0.32 0.40 0.81 1.25 2.15 1.13 1.36 2.10 2.50 2.03 3.51
Accrued Expenses		 - 0.65 0.90 2.45 1.42 1.79 2.26 2.72 4.32 3.33 3.35
Total Noncurrent Liabilities		 0.00 0.09 0.15 1.44 6.09 8.35 1.48 0.41 5.33 0.36 0.27
Other Noncurrent Operating Liabilities		 - - 0.00 1.33 6.09 8.35 1.48 0.41 5.33 0.36 0.27
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -0.74 15 17 14 16 18 79 52 26 11 15
Total Preferred & Common Equity		 -0.74 15 17 14 16 18 79 52 26 11 15
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 -0.74 15 17 14 16 18 79 52 26 11 15
Common Stock		 0.00 20 32 41 55 75 152 154 158 184 221
Retained Earnings		 -0.75 -4.68 -14 -26 -40 -57 -73 -102 -132 -172 -206
Accumulated Other Comprehensive Income / (Loss)		 - - - - - - 0.04 - - -0.04 0.01

Quarterly Balance Sheets for Moleculin Biotech

This table presents Moleculin Biotech's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 40 31 26 23 21 22 20 23
Total Current Assets		 28 19 14 12 9.34 9.08 7.89 11
Cash & Equivalents		 25 17 11 9.41 7.72 7.56 6.70 10
Prepaid Expenses		 3.02 2.13 2.89 2.20 1.62 1.52 1.18 0.64
Plant, Property, & Equipment, net		 0.23 0.24 0.22 0.19 0.13 0.10 0.08 0.07
Total Noncurrent Assets		 12 12 12 12 12 12 12 12
Goodwill		 11 11 11 11 11 11 11 11
Other Noncurrent Operating Assets		 0.55 0.50 0.48 0.45 0.40 1.27 1.24 1.18
Total Liabilities & Shareholders' Equity		 40 31 26 23 21 22 20 23
Total Liabilities		 4.39 9.26 7.87 16 21 29 47 8.18
Total Current Liabilities		 3.89 5.41 5.75 5.59 6.90 7.91 5.68 7.96
Accounts Payable		 2.01 2.10 2.83 2.55 2.71 3.72 2.12 4.57
Accrued Expenses		 1.88 3.30 2.91 3.04 4.19 4.19 3.57 3.39
Total Noncurrent Liabilities		 0.50 3.85 2.12 10 14 21 42 0.22
Other Noncurrent Operating Liabilities		 0.50 3.85 2.12 10 14 21 42 0.22
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 35 22 18 7.48 0.04 -7.17 -27 15
Total Preferred & Common Equity		 35 22 18 7.48 0.04 -7.17 -27 15
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 35 22 18 7.48 0.04 -7.17 -27 15
Common Stock		 156 158 159 159 160 160 195 234
Retained Earnings		 -121 -137 -141 -151 -160 -167 -222 -219
Accumulated Other Comprehensive Income / (Loss)		 - - - - - -0.04 - -0.05

Annual Metrics And Ratios for Moleculin Biotech

This table displays calculated financial ratios and metrics derived from Moleculin Biotech's official financial filings.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 12,054,813.00 21,136,059.00 27,129,510.00 45,727,700.00 62,464,564.00 28,577,088.00 28,627,827.00 29,810,443.00 3,001,895.00 50,910,476.00
DEI Adjusted Shares Outstanding		 893.00 1,566.00 2,010.00 3,387.00 4,627.00 76,206.00 76,341.00 79,495.00 120,076.00 2,036,419.00
DEI Earnings Per Adjusted Shares Outstanding		 -4,396.42 -6,261.18 -5,908.46 -3,898.73 -3,750.81 -208.57 -380.20 -374.48 -216.93 -16.53
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 0.00% -184.37% -7.14% -12.16% -29.80% 6.51% -81.23% -6.60% 14.63% -26.55%
EBIT Growth		 0.00% -184.39% -7.58% -13.19% -29.37% 6.65% -80.20% -6.56% 14.57% -26.29%
NOPAT Growth		 0.00% -122.84% -73.64% -16.63% -12.66% -16.34% -33.40% 3.29% 10.09% 5.77%
Net Income Growth		 0.00% -149.75% -21.12% -11.19% -31.43% 8.42% -82.62% -2.56% 12.50% -28.84%
EPS Growth		 0.00% -32.50% 13.21% -11.19% -31.43% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Growth		 0.00% -94.53% -66.62% -40.93% -3.33% -6.64% -45.84% 14.65% -1.15% 4.72%
Free Cash Flow Firm Growth		 0.00% 0.00% -58.31% -20.76% -16.11% -86.52% -3.82% 36.54% -62.15% 27.26%
Invested Capital Growth		 0.00% -8.24% -24.10% -32.25% -46.51% 212.72% 11.82% -72.11% 174.67% -11.57%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% -19.15% 3.59% -8.21% 6.17% -1.68% -15.79% -13.34% 2.75% 25.43%
EBIT Q/Q Growth		 0.00% -19.13% 3.29% -8.17% 6.13% -1.59% -15.70% -13.29% 2.75% 25.41%
NOPAT Q/Q Growth		 0.00% -29.63% -6.71% -2.78% 6.26% -8.05% -6.40% -6.74% 7.87% -3.68%
Net Income Q/Q Growth		 0.00% -21.92% 3.26% -8.30% 6.26% -1.19% -15.73% -13.32% 2.01% 25.30%
EPS Q/Q Growth		 0.00% -6.00% 0.00% -8.30% 6.26% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 0.00% -20.01% -6.27% -10.03% 8.04% -6.36% -12.17% 9.09% -0.79% -1.26%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% -48.25% -9.11% 9.94% -11.88% -1.36% 35.27% -197.26% -213.71%
Invested Capital Q/Q Growth		 0.00% -11.77% 12.09% 35.61% 54.72% 33.04% 12.72% -76.11% 459.81% 118.23%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 98.30% 99.84% 99.75% 100.00% 99.84% 99.84% 100.06%
Interest Burden Percent		 101.11% 88.79% 99.97% 99.90% 99.93% 98.12% 99.18% 95.61% 97.94% 99.69%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -55.24% -61.13% -75.67% -88.50% -104.14% -32.85% -44.25% -76.07% -139.74% -256.05%
Cash Return on Invested Capital (CROIC)		 0.00% -53.04% -99.76% -166.44% -311.74% -404.24% -261.48% -245.81% -487.80% -256.86%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -55.24% -61.13% -75.67% -88.50% -104.14% -32.85% -44.25% -76.07% -139.74% -256.05%
Return on Equity Simple (ROE_SIMPLE)		 -26.24% -57.28% -83.21% -84.81% -97.72% -20.12% -55.61% -114.18% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -2.72 -6.06 -11 -12 -14 -16 -21 -21 -19 -18
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -25.64% -60.33% -18.30% -10.50% -27.29% 0.43% -13.29% -27.07% -53.18% -243.05%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - -79.55% -166.39% -117.10%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -3.88 -11 -12 -13 -17 -16 -29 -31 -27 -34
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -3.88 -11 -12 -13 -17 -16 -29 -31 -27 -34
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 1.84 2.30 1.98 2.69 2.80 0.67 0.58 0.98 0.46 0.45
Price to Tangible Book Value (P/TBV)		 7.21 6.59 9.03 9.46 7.53 0.78 0.74 1.71 85.05 1.75
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 2.22 3.36 2.95 6.43 13.38 0.00 0.00 0.81 0.12 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 0.02 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -0.31 -0.39 -0.47 -0.60 -0.78 -0.89 -0.87 -0.85 -0.75 -0.50
Leverage Ratio		 1.16 1.12 1.24 1.50 1.63 1.17 1.08 1.22 1.48 1.49
Compound Leverage Factor		 1.17 0.99 1.24 1.50 1.63 1.15 1.07 1.17 1.45 1.49
Debt to Total Capital		 1.94% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 1.94% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 98.06% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 -0.08 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 1.22 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 -0.11 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 1.73 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 10.61 7.44 -0.45 -0.88 -1.48 5.39 0.17 -5.64 -18.93 -17.33
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 3.88 3.75 2.06 3.78 5.89 20.02 9.46 3.86 0.97 1.41
Quick Ratio		 3.72 3.48 1.84 3.01 5.20 19.58 8.95 3.46 0.80 1.30
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -5.21 -8.25 -9.96 -12 -22 -22 -14 -23 -17
Operating Cash Flow to CapEx		 -17,928.57% -26,157.14% -2,926.38% -33,721.57% -4,751.60% -99,742.11% -41,252.24% -19,025.00% -183,553.85% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 -87.56 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 -88.05 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 10 9.40 7.14 4.84 2.59 8.09 9.05 2.52 6.93 6.13
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 0.00 -0.85 -2.27 -2.30 -2.25 5.50 0.96 -6.52 4.41 -0.80
Enterprise Value (EV)		 23 32 21 31 35 -18 -13 2.04 0.83 -2.14
Market Capitalization		 27 39 28 42 50 53 30 26 5.10 6.74
Book Value per Share		 $1.24 $0.81 $0.53 $0.34 $0.28 $2.76 $1.82 $0.87 $3.73 $0.29
Tangible Book Value per Share		 $0.32 $0.28 $0.12 $0.10 $0.11 $2.37 $1.43 $0.50 $0.02 $0.08
Total Capital		 15 17 14 16 18 79 52 26 11 15
Total Debt		 0.30 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -4.71 -7.71 -7.13 -11 -15 -71 -43 -24 -4.28 -8.88
Capital Expenditures (CapEx)		 0.02 0.03 0.42 0.05 0.37 0.02 0.07 0.12 0.01 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -0.83 -1.63 -3.04 -0.82 -0.90 -2.03 -2.37 -4.09 -4.44 -6.05
Debt-free Net Working Capital (DFNWC)		 4.17 6.09 4.10 9.91 14 69 41 19 -0.17 2.83
Net Working Capital (NWC)		 3.88 6.09 4.10 9.91 14 69 41 19 -0.17 2.83
Net Nonoperating Expense (NNE)		 1.21 3.75 1.36 0.94 3.54 -0.18 7.58 9.03 7.40 16
Net Nonoperating Obligations (NNO)		 -4.71 -7.71 -7.13 -11 -15 -71 -43 -24 -4.28 -8.88
Total Depreciation and Amortization (D&A)		 0.01 0.02 0.07 0.20 0.20 0.16 0.13 0.13 0.13 0.09
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($216.00) ($286.20) ($248.40) ($172.80) ($26.40) ($8.85) ($15.15) ($226.05) ($158.00) ($28.42)
Adjusted Weighted Average Basic Shares Outstanding		 31.81K 47.72K 52.83K 98.57K 1.90M 1.91M 1.91M 131.71K 137.72K 1.18M
Adjusted Diluted Earnings per Share		 ($216.00) ($286.20) ($248.40) ($172.80) ($26.40) ($8.85) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Diluted Shares Outstanding		 31.81K 47.72K 52.83K 98.57K 1.90M 1.91M 1.91M 148.50K 560.02K 5.34M
Adjusted Basic & Diluted Earnings per Share		 ($216.00) ($286.20) ($248.40) ($172.80) ($26.40) ($8.85) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 18.20K 34.39K 47.97K 75.41K 656.38K 1.79M 1.91M 148.50K 560.02K 5.34M
Normalized Net Operating Profit after Tax (NOPAT)		 -2.72 -6.06 -11 -12 -14 -16 -21 -21 -19 -18
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 -90.30 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 -63.21 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 -90.79 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 -63.70 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Moleculin Biotech

This table displays calculated financial ratios and metrics derived from Moleculin Biotech's official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 29,810,443.00 29,810,443.00 2,227,516.00 2,311,536.00 2,561,527.00 3,001,895.00 14,000,494.00 14,127,494.00 30,286,168.00 50,910,476.00 5,336,350.00
DEI Adjusted Shares Outstanding		 79,495.00 79,495.00 5,940.00 92,461.00 102,461.00 120,076.00 560,020.00 565,100.00 1,211,447.00 2,036,419.00 5,336,350.00
DEI Earnings Per Adjusted Shares Outstanding		 -70.56 -129.18 -836.70 -46.71 -68.55 -81.07 -10.54 -13.52 -20.97 2.85 -2.74
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 31.32% -53.29% 37.36% 29.73% -20.08% 7.13% -13.91% -71.42% -258.05% 161.07% -119.00%
EBIT Growth		 31.21% -53.08% 37.20% 29.58% -20.00% 7.15% -13.81% -70.86% -256.75% 160.79% -117.99%
NOPAT Growth		 34.53% -26.55% 20.07% 3.53% -19.98% 25.51% 10.99% 7.52% 17.22% -61.99% -32.49%
Net Income Growth		 34.86% -51.68% 37.21% 27.73% -25.23% 5.20% -18.79% -76.89% -261.60% 160.76% -117.56%
EPS Growth		 0.00% -51.68% 0.00% 0.00% 0.00% 5.20% 0.00% 0.00% 0.00% 106.95% 0.00%
Operating Cash Flow Growth		 0.34% 32.51% -11.63% -16.06% 19.04% -3.80% 32.05% 6.17% -18.16% -5.57% -33.90%
Free Cash Flow Firm Growth		 19.34% 104.75% 86.79% 26.76% 211.85% -3,338.40% 913.13% 668.22% 267.97% 25.68% -318.10%
Invested Capital Growth		 31.58% -72.11% -43.43% -15.27% -118.24% 174.67% -261.12% -314.61% -1,645.74% -11.57% 163.41%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 6.76% -77.75% 50.64% 14.10% -59.33% -37.46% 39.45% -18.59% -232.79% 123.45% -317.12%
EBIT Q/Q Growth		 6.73% -77.41% 50.50% 14.04% -58.94% -37.28% 39.33% -18.46% -231.86% 123.39% -317.58%
NOPAT Q/Q Growth		 7.24% -49.97% 25.14% 7.37% -15.36% 6.88% 10.55% 3.75% -3.25% -82.24% 26.84%
Net Income Q/Q Growth		 6.14% -83.08% 51.60% 13.10% -62.63% -38.60% 39.35% -18.71% -232.45% 123.29% -317.16%
EPS Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 -47.31% 35.15% -37.17% 11.43% -2.76% 16.85% 10.21% -22.31% -29.40% 25.71% -13.88%
Free Cash Flow Firm Q/Q Growth		 -58.56% 104.18% -463.93% -203.91% 342.14% -220.92% 191.38% 112.37% 56.80% -124.42% -168.15%
Invested Capital Q/Q Growth		 30.42% -76.11% 88.78% 44.03% -128.08% 459.81% -210.74% -91.84% -128.39% 118.23% -20.59%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 99.77% 99.83% 99.78% 99.75% 99.87% 99.88% 99.85% 99.95% 99.94% 99.18% 99.41%
Interest Burden Percent		 94.55% 97.52% 95.38% 96.46% 98.57% 99.51% 99.50% 99.66% 99.85% 100.17% 99.74%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -56.16% -76.07% -79.75% -86.82% -124.75% -139.74% -249.50% -503.80% 462.17% -256.05% -532.03%
Cash Return on Invested Capital (CROIC)		 -236.40% -245.81% -241.42% -243.03% 0.00% -487.80% 0.00% 0.00% 0.00% -256.86% -646.61%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -56.16% -76.07% -79.75% -86.82% -124.75% -139.74% -249.50% -503.80% 462.17% -256.05% -532.03%
Return on Equity Simple (ROE_SIMPLE)		 -74.76% 0.00% -124.26% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -4.16 -6.24 -4.67 -4.33 -4.99 -4.65 -4.16 -4.00 -4.13 -7.53 -5.51
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -3.86% -12.07% -1.09% 0.05% -11.94% -36.54% -14.21% -39.52% -264.03% 204.45% -81.33%
Return On Investment Capital (ROIC_SIMPLE)		 - -23.95% -21.65% -24.45% -66.78% -41.50% -9,905.00% 55.88% 15.36% -50.21% -36.30%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -5.95 -11 -5.22 -4.49 -7.14 -9.80 -5.94 -7.67 -25 5.95 -13
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -5.92 -11 -5.19 -4.46 -7.10 -9.76 -5.91 -7.64 -25 5.96 -13
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.36 0.98 0.04 0.46 0.97 0.46 324.54 0.00 0.00 0.45 0.80
Price to Tangible Book Value (P/TBV)		 0.53 1.71 0.08 1.24 0.00 85.05 0.00 0.00 0.00 1.75 3.03
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.81 0.00 0.00 0.00 0.12 0.00 0.00 0.00 0.00 0.39
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.63 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -0.80 -0.85 -0.80 -0.74 -0.80 -0.75 -1.13 -1.75 0.83 -0.50 -1.18
Leverage Ratio		 1.12 1.22 1.22 1.25 1.48 1.48 2.40 4.48 -2.25 1.49 2.91
Compound Leverage Factor		 1.06 1.19 1.16 1.21 1.46 1.47 2.39 4.46 -2.25 1.49 2.91
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 -2.33 -3.86 -6.17 -7.30 -9.49 -15.65 -11.05 -11.87 -19.03 -11.43 -13.89
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 7.10 3.86 3.51 2.39 2.08 0.97 1.35 1.15 1.39 1.41 1.38
Quick Ratio		 6.32 3.46 3.11 1.89 1.68 0.80 1.12 0.96 1.18 1.30 1.30
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -6.70 0.28 -1.02 -3.09 7.49 -9.06 8.28 18 28 -6.73 -18
Operating Cash Flow to CapEx		 -26,967.86% -6,045.68% 0.00% -45,761.54% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 11 2.52 4.76 6.86 -1.93 6.93 -7.67 -15 -34 6.13 4.87
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 2.53 -6.52 -3.66 -1.24 -12 4.41 -12 -22 -32 -0.80 13
Enterprise Value (EV)		 -12 2.04 -16 -2.71 -2.13 0.83 5.91 -3.29 9.35 -2.14 1.90
Market Capitalization		 13 26 0.88 8.14 7.27 5.10 14 4.27 16 6.74 12
Book Value per Share		 $1.18 $0.87 $9.69 $7.66 $2.92 $3.73 $0.00 ($0.51) ($0.89) $0.29 $2.85
Tangible Book Value per Share		 $0.80 $0.50 $4.69 $2.84 ($1.43) $0.02 ($0.79) ($1.30) ($1.26) $0.08 $0.76
Total Capital		 35 26 22 18 7.48 11 0.04 -7.17 -27 15 15
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -25 -24 -17 -11 -9.41 -4.28 -7.72 -7.56 -6.70 -8.88 -10
Capital Expenditures (CapEx)		 0.03 0.08 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -0.86 -4.09 -3.28 -2.86 -3.39 -4.44 -5.27 -6.39 -4.50 -6.05 -7.32
Debt-free Net Working Capital (DFNWC)		 24 19 14 7.99 6.01 -0.17 2.44 1.16 2.20 2.83 3.00
Net Working Capital (NWC)		 24 19 14 7.99 6.01 -0.17 2.44 1.16 2.20 2.83 3.00
Net Nonoperating Expense (NNE)		 1.45 4.03 0.30 -0.01 2.03 5.08 1.74 3.64 21 -13 7.33
Net Nonoperating Obligations (NNO)		 -25 -24 -17 -11 -9.41 -4.28 -7.72 -7.56 -6.70 -8.88 -10
Total Depreciation and Amortization (D&A)		 0.03 0.04 0.03 0.03 0.03 0.03 0.03 0.03 0.02 0.01 0.01
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($2.85) ($78.00) ($2.02) ($1.70) ($2.85) ($1,767.25) ($17.25) ($0.49) ($0.68) $4.91 ($3.54)
Adjusted Weighted Average Basic Shares Outstanding		 1.99M 131.71K 2.47M 2.54M 3.71M 5.51K 373.75K 15.53M 37.30M 1.18M 4.12M
Adjusted Diluted Earnings per Share		 $0.00 ($78.00) $0.00 $0.00 $0.00 ($1,767.25) $0.00 $0.00 $0.00 $4.91 $0.00
Adjusted Weighted Average Diluted Shares Outstanding		 1.99M 148.50K 2.31M 2.56M 3.00M 560.02K 565.10K 30.29M 50.91M 5.34M 5.34M
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($78.00) $0.00 $0.00 $0.00 ($1,767.25) $0.00 $0.00 $0.00 $4.91 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 1.99M 148.50K 2.31M 2.56M 3.00M 560.02K 565.10K 30.29M 50.91M 5.34M 5.34M
Normalized Net Operating Profit after Tax (NOPAT)		 -4.16 -6.24 -4.67 -4.33 -4.99 -4.65 -4.16 -4.00 -4.13 -5.27 -5.51
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Moleculin Biotech (NASDAQ: MBRX) remains a highly cash-consuming clinical-stage biotech with no product revenue, but its financial profile has changed dramatically over the past year. The latest Q1 2026 filing shows a much smaller balance sheet than a year ago, continued operating losses, and a reliance on equity issuance to fund operations. The company is still very much in “financing mode,” which is common for development-stage biotechs, but the trends point to meaningful dilution and a shrinking liquidity cushion.

  • Cash increased sequentially in Q1 2026 to $10.3 million from $6.7 million in Q3 2025, helped by $7.6 million of common equity issuance and a $1.44 million net increase in cash for the quarter.
  • Operating cash burn improved versus prior quarters, with Q1 2026 operating cash outflow of $6.1 million versus $7.2 million in Q3 2025 and $5.6 million in Q2 2025.
  • Operating expenses were lower than in Q4 2025, with total operating expenses of $7.9 million in Q1 2026 versus $7.5 million in Q4 2025 and $5.9 million in Q3 2025 on a quarterly basis.
  • R&D spending is still being supported, and that matters for a biotech: Q1 2026 R&D expense was $5.4 million, indicating continued pipeline investment.
  • There is no revenue yet, so the investment thesis still depends entirely on clinical and financing execution.
  • Goodwill remains a large asset on the balance sheet at $11.1 million, which is meaningful relative to total assets of $23.4 million.
  • Quarterly results are volatile, especially in “other income/expense,” which swung from a large gain in Q4 2025 to a $5.1 million loss in Q1 2026.
  • MBRX posted a net loss of $12.8 million in Q1 2026, or $14.6 million attributable to common shareholders after preferred dividends.
  • The company has a substantial accumulated deficit, with retained earnings of negative $218.8 million at Q1 2026.
  • Share dilution is a major issue: weighted average diluted shares were 5.3 million in Q1 2026, and the company has repeatedly relied on equity issuance to fund operations.
  • Balance sheet leverage and equity have weakened sharply year over year, with total equity falling to $15.2 million in Q1 2026 from $42,000 in Q1 2025 and $7.5 million in Q3 2024, while liabilities rose to $8.2 million.
  • Cash has declined materially over the last 12 months, from $16.8 million in Q1 2024 and $7.7 million in Q1 2025 to $10.3 million in Q1 2026, showing the ongoing funding challenge.
  • Historically, operating losses have been persistent and large, with quarterly net losses generally ranging from about $4.7 million to over $25 million in the last several years, underscoring the company’s dependence on outside capital.

Bottom line: Moleculin Biotech is still a speculative, capital-dependent biotech. The good news is that cash improved in the latest quarter and operating burn was somewhat better than recent periods. The bad news is that losses remain heavy, dilution is ongoing, and the company still lacks revenue. For retail investors, this is a name where clinical progress and financing activity will likely matter more than traditional profitability metrics for the foreseeable future.

07/25/26 04:29 PM ETAI Generated. May Contain Errors.

Moleculin Biotech Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Moleculin Biotech's fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Moleculin Biotech's net income appears to be on an upward trend, with a most recent value of -$33.56 million in 2025, rising from -$3.93 million in 2016. The previous period was -$26.05 million in 2024. See where experts think Moleculin Biotech is headed by visiting Moleculin Biotech's forecast page.

Moleculin Biotech's total operating income in 2025 was -$25.10 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $25.10 million

Over the last 9 years, Moleculin Biotech's total revenue changed from $0.00 in 2016 to $0.00 in 2025, a change of 0.0%.

Moleculin Biotech's total liabilities were at $7.12 million at the end of 2025, a 24.5% increase from 2024, and a 821.3% increase since 2015.

In the past 10 years, Moleculin Biotech's cash and equivalents has ranged from $28.09 thousand in 2015 to $70.90 million in 2021, and is currently $8.88 million as of their latest financial filing in 2025.

Over the last 9 years, Moleculin Biotech's book value per share changed from 1.24 in 2016 to 0.29 in 2025, a change of -76.2%.


Related Companies

Financial statements for NASDAQ:MBRX last updated on 7/16/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
Three oil giants buried the same discovery for 50 years
In 1976, Chevron tapped an energy source with no fuel costs, no carbon, and no supply chain - then killed the ...
Behind the Markets | Sponsoredtc pixel
Elon's new "super startup"
Adam O'Dell - the analyst who recommended Palantir before it became the top S&P 500 performer - has identified...
Banyan Hill Publishing | Sponsoredtc pixel